VITA 34 AG(VTIAF)
USD --+0.00%
Reward53Moderate
Risk62Medium-High
📊75%Data
Thin -11% profit margin
VTIAF
+0.0 · +0.00%
USD · PINK
VITA 34 AG | Healthcare
Profitless Growth
Market Cap:139.84M
ℹ️
Reward Rating
53
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
62
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on VTIAF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is VITA 34 AG?

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally.

VTIAF · Verdict

Moderate reward · elevated risk

VTIAF stands out on growth and volatility, but watch the profitability signal.

Based on 88% data coverage

VTIAF · Verdict

What’s working & what to watch

Strengths 2

  • Growth74/100

    Rev +42.5% CAGR · earnings +49.0%

  • Volatility65/100

    Above average

Watchouts 4

  • Profitability21/100

    -15% net margin · -58% ROE

  • Balance sheet21/100

    Current ratio 0.73

  • Cash flow36/100

    7% free-cash-flow margin

  • Valuation42/100

    Below average

Model-based scoring. For information only — not financial advice.

What is VITA 34 AG?

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 139.84M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap139.84M
P/E RatioN/A
Dividend YieldN/A
52 Week High7
52 Week Low4.52
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding17M
No. of Employees771
IndustryMedical Care Facilities
ExchangePINK
Beta0.722
CurrencyUSD · Reports in EUR